CLINICAL_TRIALS
trial_result
· 2017-05-15
Clinical Trial Update: Imatinib Mesylate in Treating Patients With Recurrent Meningioma [Phase 2]
Summary
Phase 2 trial evaluating imatinib mesylate in patients with recurrent meningioma completed; results posted in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Cancer Institute (NCI) | Conditions: Adult Grade I Meningioma, Adult Grade II Meningioma | Phase 2 | Status: COMPLETED | Results posted: 2017-05-15